- The Biotech Act aims to mobilize €10 billion investment for Europe's biotech sector.
- Cardiovascular diseases cost the EU economy €282 billion annually.
- Medical device reforms could save €3.3 billion per year, including €2.4 billion in administrative savings.
- The Safe Hearts Plan sets clear goals for cardiovascular health improvements by 2035.
Overview
The European Commission has proposed measures to enhance the EU health sector's innovation, competitiveness, and resilience. This includes the Biotech Act, Safe Hearts Plan, and medical device reforms.
Biotech Act
The Biotech Act aims to boost Europe's biotechnology sector, which contributes €40 billion to the economy and employs over 900,000 people. It addresses funding gaps and regulatory barriers, promoting research and production within Europe. The Act will explore new funding methods and accelerate clinical trials, aiming to establish a leading health biotech industry.
Safe Hearts Plan
Cardiovascular diseases, the leading cause of premature death in the EU, cost the economy €282 billion annually. The Safe Hearts Plan is the first comprehensive EU approach to tackle this issue, focusing on prevention, detection, and treatment. It aims to reduce health inequalities and improve access to care, with goals set for 2035.
Medical Devices
The EU's medical device sector, valued at €170 billion, faces regulatory challenges. Proposed reforms aim to simplify rules, support digitalization, and ensure patient safety. The European Medicines Agency will play a stronger role in coordination and monitoring shortages. These changes could lead to €3.3 billion in annual savings, including €2.4 billion in administrative costs.
Next Steps
The legislative proposals will be submitted to the European Parliament and the Council for adoption. Implementation of the Safe Hearts Plan will begin in collaboration with Member States.
